MetaCap

BridgeBio Oncology Therapeutics (BBOT) vs ProQR Therapeutics N.V. (PRQR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

ProQR Therapeutics N.V. (PRQR) has outperformed BridgeBio Oncology Therapeutics (BBOT) over the past year, losing 49.5% versus a loss of 85.4%. ProQR Therapeutics N.V. is the larger company by market cap ($147.0 million vs $145.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BBOT-85.39%PRQR-49.51%
+24%-33%-91%
Nov 21, 20251 yearNov 20, 2026
BBOT-82.24%PRQR-52.73%
+106%+7%-91%
Feb 5, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BBOT versus PRQR key metrics
MetricBBOTPRQR
Share price$1.81$1.04
Market cap$145.25M$146.98M
1-day change-2.69%-0.95%
YTD return-85.54%-48.51%
1-year return-85.39%-49.51%
5-year return—-85.54%
P/E ratio (TTM)3.42—
EPS (TTM)$0.53$-0.43
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-134.04M—
52-week high$14.87$2.49
52-week low$1.79$1.00
Distance from 52-week high-87.83%-58.15%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1060.22%+626.92%
Average volume631.56K793.64K
Shares outstanding80.25M141.33M
Employees92186
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PRQR has outperformed BBOT by 35.9 percentage points over the past year.

About BridgeBio Oncology Therapeutics

BBOT stock →

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.

Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees

About ProQR Therapeutics N.V.

PRQR stock →

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs.

Health Care · Biotechnology: Pharmaceutical Preparations · 186 employees

BBOT vs PRQR FAQ

Which is bigger, BridgeBio Oncology Therapeutics or ProQR Therapeutics N.V.?

ProQR Therapeutics N.V. (PRQR) is larger, with a market capitalization of $146.98M compared with $145.25M for BridgeBio Oncology Therapeutics (BBOT).

Which stock has performed better over the past year, BBOT or PRQR?

PRQR returned -49.51% over the past 12 months, compared with -85.39% for BBOT (price return, excluding dividends). Past performance does not predict future results.

Are BridgeBio Oncology Therapeutics and ProQR Therapeutics N.V. in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons